People · Operator
Named in public records as an officer, director or promoter · active 2016–2018 · Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Front Range Biosciences, Inc. | — | Biotech / Pharma | Series B | $45.0M | $689.5M | 2016 |
Christopher Zalewski at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Zalewski on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ephraim Lindenbaum | 1 | 5 |
| Marc Riiska | 1 | 4 |
| Nicholas Hofmeister | 1 | 2 |
| Nick Hofmeister | 1 | 2 |
| William Militello | 1 | 1 |
| Jonathan Vaught | 1 | 1 |
| Douglas Wolford | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.